New vaccine for Omicron may be ready in early 2022, says Moderna

accreditation
0:00
play article
Subscribers can listen to this article
Photo: Getty
Photo: Getty

Moderna Chief Medical Officer Paul Burton said he suspects the new omicron coronavirus variant may elude current vaccines, and if so, a reformulated shot could be available early in the new year.  

"We should know about the ability of the current vaccine to provide protection in the next couple of weeks," Burton said Sunday on the BBC’s “Andrew Marr Show.”

“If we have to make a brand new vaccine, I think that’s going to be early 2022 before that’s really going to be available in large quantities,” he said. “The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast,” he said.  

The Cambridge, Massachusetts-based biotech company mobilised “hundreds” of staff early on Thursday, Thanksgiving Day in the US, after news of the omicron variant spread. 

Protection should still exist, depending on how long ago a person was vaccinated, and for now the best advice is to take one of the current Covid-19 vaccines, Burton said.

“If people are on the fence, and you haven’t been vaccinated, get vaccinated,” he said. “This is a dangerous looking virus, but I think we have many tools in our armamentarium now to fight it.”  

The emergence of the omicron strain has seen countries rush to clamp down on travel from southern Africa. Fears that it could exacerbate a winter Covid surge in the northern hemisphere and undermine a global economic recovery sent a wave of risk aversion across global markets Friday that continued Sunday when the Middle East opened for the week. 

Moderna said in a release on Friday that it was working rapidly to test the current vaccine against the omicron variant, and studying two booster candidates.  

“Since early 2021, Moderna has advanced a comprehensive strategy to anticipate new variants of concern,” the company said. “The company has repeatedly demonstrated the ability to advance new candidates to clinical testing in 60 to 90 days.”   

We live in a world where facts and fiction get blurred
In times of uncertainty you need journalism you can trust. For only R75 per month, you have access to a world of in-depth analyses, investigative journalism, top opinions and a range of features. Journalism strengthens democracy. Invest in the future today.
Subscribe to News24
Rand - Dollar
15.43
-0.3%
Rand - Pound
20.95
+0.1%
Rand - Euro
17.54
+0.0%
Rand - Aus dollar
11.09
+0.0%
Rand - Yen
0.13
-0.2%
Gold
1,817.27
-0.1%
Silver
23.45
+1.8%
Palladium
1,900.50
+1.2%
Platinum
982.00
+0.6%
Brent Crude
86.48
+0.5%
Top 40
68,203
-1.0%
All Share
74,865
-1.0%
Resource 10
74,398
-0.4%
Industrial 25
94,205
-1.4%
Financial 15
15,317
-1.2%
All JSE data delayed by at least 15 minutes Iress logo
Company Snapshot